Menu: Home :: go to Journal :: switch to Russian :: switch to English
You are here: all Journals and Issues→ Journal→ Issue→ Article

Vascular endothelial growth factor, interferons of alpha and gamma in the serum of Ewing’s sarcoma patients

Annotation

Study aim : vascular endothelial growth factor (VEGF) and interferons (IFN-alpha and IFN-gamma) levels determination in blood serum of Ewing’s sarcoma patients and age-matched healthy persons in order to identify possible associations with clinical features and prognosis of the disease. Materials and methods : the study enclosed 28 Ewing’s sarcoma patients: 24 men and 4 women aged 14-50 years (median - 20). The control group consisted of 14 healthy subjects, 8 males and 6 females aged 14-30 years (median - 22.5). In all patients the diagnosis was established for the first time and was confirmed by histological examination of the tumor. Identification of all parameters was carried out before the start of specific treatment using chemicals of the firm: “Bender MedSystems” (Austria) for IFN-alpha and IFN-gamma, “R&D” (USA) - for VEGF. Results : overall 3- and 5-year’s survival rate of patients with Ewing’s sarcoma with serum VEGF content in less than 560 pg/ml was 3 times higher ( p = 0.003) than of those with VEGF levels more than 560 pg/ml. No significant differences in overall survival of Ewing’s sarcoma patients depending on IFN-gamma levels in blood serum were found. Positive correlation between pre-treatment IFN-gamma and IFN-alpha serum levels with the maximum correlation coefficient ( r = 0.88; p = 0.021) was revealed in Ewing’s sarcoma patients who subsequently died of disease progression. Conclusion : our findings suggest that VEGF, IFN-gamma and IFN-alpha could be related to pathogenetic changes associated with growth and metastasis of Ewing’s sarcoma. So, these markers may be the subject of further studies of their prognostic significance in this severe disease.

Keywords

Ewing’s sarcoma; IFN-gamma; IFN-alpha; VEGF

Full-text in one file

Download

DOI

10.20310/1810-0198-2017-22-1-136-141

Pages

136-141

References

1. de Alava E., Kawai A., Healey J.H., Fligman I., Meyers P.A., Huvos A.G., Gerald W.L., Jhanwar S.C., Argani P., Antonescu C.R., Pardo-Mindan F.J., Ginsberg J., Womer R., Lawlor E.R., Wunder J., Andrulis I., Sorensen P.H., Barr F.G., Ladanyi M. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J. Clin. Oncol., 1998, vol. 16 (4), pp. 1248-1255. 2. Wang J., Jiang W., Yan Y., Chen C., Yu Y., Wang B., Zhao H. Knockdown of EWSR1/FLI1 expression alters the transcriptome of Ewing sarcoma cells in vitro. J. Bone Oncol., 2016, vol. 5 (4), pp. 153-158. 3. Mackintosh C., Madoz-Gúrpide J., Ordóñez J.L., Osuna D., Herrero-Martín D. The molecular pathogenesis of Ewing's sarcoma. Cancer Biol. Ther., 2010, vol. 9 (9), pp. 655-667. 4. Boehme K.A., Nitsch J., Riester R., Handgretinger R., Schleicher S.B., Kluba T., Traub F. Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. Int. J. Oncol., 2016, vol. 49 (5), pp. 2135-2146. 5. van Maldegem A.M., Hogendoorn P.C., Hassan A.B. The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin. Sarcoma Res., 2012, vol. 2 (1), p. 7. 6. Radic-Sarikas B., Tsafou K.P., Emdal K.B., Papamarkou T., Huber K.V., Mutz C., Toretsky J.A., Bennett K.L., Olsen J.V., Brunak S., Kovar H., Superti-Furga G. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. Mol. Cancer Ther., 2017, vol. 16 (1), pp. 88-101. 7. Nasaka S., Gundeti S., Ganta R.R., Arigela R.S., Linga V.G., Maddali L.S. Impact of treatment protocol on outcome of localized Ewing's sarcoma. South Asian J. Cancer, 2016, vol. 5 (4), pp. 194-195. 8. Biologicheskie markery opukholey: fundamental'nye i klinicheskie issledovaniya [Biological Markers of Tumours: Fundamental and Clinical Researches]. N.E. Kushlinskiy, M.A. Krasil'nikov (eds.). Moscow, Russian Academy of Medical Sciences Publ., 2017, 632 p. (In Russian). 9. Mariño-Enríquez A., Fletcher C.D. Round cell sarcomas – biologically important refinements in subclassification. Int. J. Biochem. Cell. Biol., 2014, vol. 53, pp. 493-504. 10. Katuri V., Gerber S., Qiu X., McCarty G., Goldstein S.D., Hammers H., Montgomery E., Chen A.R., Loeb D.M. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget, 2014, vol. 5 (9), pp. 2436-2449. 11. Hauer K., Calzada-Wack J., Steiger K., Grunewald T.G., Baumhoer D., Plehm S., Buch T., Prazeres da Costa O., Esposito I., Burdach S., Richter G.H. DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res., 2013, vol. 73 (2), pp. 967-977. 12. Smith M.A., Altekruse S.F., Adamson P.C., Reaman G.H., Seibel N.L. Declining childhood and adolescent cancer mortality. Cancer, 2014, vol. 120 (16), pp. 2497-2506. 13. Bacci G., Ferrari S., Bertoni F., Rimondini S., Longhi A., Bacchini P., Forni C., Manfrini M., Donati D., Picci P. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J. Clin. Oncol., 2000, vol. 18 (1), pp. 4-11. 14. Lee J., Hoang B.Y., Ziogas A., Zell J.A. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer, 2010, vol. 116 (8), pp. 1964-1973. 15. Kumar R., Sankineani S., Rastogi S., Prakash S., Bakhshi S., Sharma M.C., Khan S., Sagar D.C.G., Rijal L. Expression of vascular endothelial growth factor in Ewing's sarcoma. Int. Orthop., 2012, vol. 36 (8), pp. 1669-1672. 16. Shukla N., Schiffman J., Reed D., Davis I.J., Womer R.B., Lessnick S.L., Lawlor E.R. COG Ewing Sarcoma Biology Committee. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children’s Oncology Group. Front. Oncol., 2013, vol. 3, pp. 141.

Received

2017-01-25

Section of issue

Medicine

Для корректной работы сайта используйте один из современных браузеров. Например, Firefox 55, Chrome 60 или более новые.